Oruka Therapeutics (NASDAQ:ORKA) Shares Up 9% – Here’s Why

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares shot up 9% on Thursday . The stock traded as high as $69.72 and last traded at $69.7890. 253,552 shares changed hands during mid-day trading, a decline of 76% from the average session volume of 1,066,309 shares. The stock had previously closed at $64.03.

Analyst Ratings Changes

Several research firms have recently weighed in on ORKA. Wedbush set a $165.00 target price on shares of Oruka Therapeutics in a research report on Monday, April 27th. UBS Group boosted their target price on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Piper Sandler reissued an “overweight” rating and issued a $180.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Leerink Partners set a $120.00 target price on shares of Oruka Therapeutics in a research report on Thursday, April 30th. Finally, Barclays boosted their price objective on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research report on Monday, April 27th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $131.30.

Oruka Therapeutics Trading Up 8.0%

The stock has a market cap of $4.17 billion, a P/E ratio of -35.49 and a beta of -0.26. The firm’s 50-day simple moving average is $62.62 and its 200 day simple moving average is $43.49.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.04. On average, analysts anticipate that Oruka Therapeutics, Inc. will post -2.06 EPS for the current year.

Insider Activity at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $61.85, for a total value of $432,950.00. Following the completion of the sale, the insider directly owned 33,377 shares of the company’s stock, valued at approximately $2,064,367.45. This represents a 17.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the sale, the chief executive officer owned 927,309 shares in the company, valued at $38,297,861.70. This represents a 0.19% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 139,055 shares of company stock valued at $8,095,785. 23.49% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Oruka Therapeutics

A number of large investors have recently made changes to their positions in the company. Fairmount Funds Management LLC raised its holdings in shares of Oruka Therapeutics by 9.9% during the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after acquiring an additional 333,340 shares during the period. Viking Global Investors LP acquired a new position in Oruka Therapeutics in the 3rd quarter valued at approximately $51,280,000. Deep Track Capital LP increased its stake in Oruka Therapeutics by 38.4% in the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after buying an additional 735,983 shares during the period. Vanguard Group Inc. increased its stake in Oruka Therapeutics by 38.1% in the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock valued at $74,366,000 after buying an additional 676,865 shares during the period. Finally, RTW Investments LP increased its stake in Oruka Therapeutics by 5.8% in the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock valued at $62,382,000 after buying an additional 112,499 shares during the period. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.